Leuprorelin: a leading role in advanced prostate cancer therapy.
Leuprorelin is a luteinizing hormone-releasing hormone analogue, licensed in the UK for the treatment of advanced prostate cancer. This review highlights the efficacy and tolerance of this agent and the benefits provided for developing patient-centred therapy and optimizing patient quality of life.
Persad
Raj
R
Bristol Royal Infirmary, University of Bristol.
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005544:Forecasting; D006801:Humans; D016729:Leuprolide / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D008863:Microspheres; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D016729:Leuprolide